These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. Garcia-Manero G; Fenaux P J Clin Oncol; 2011 Feb; 29(5):516-23. PubMed ID: 21220589 [TBL] [Abstract][Full Text] [Related]
7. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm. Merkel DG; Nagler A Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866 [TBL] [Abstract][Full Text] [Related]
8. Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy. Stone R; Sekeres M; Garcia-Manero G; Lyons RM Clin Adv Hematol Oncol; 2008 Dec; 6(12):1-15. PubMed ID: 19385003 [TBL] [Abstract][Full Text] [Related]
9. Management of myelodysplastic syndromes: 2008 update. Scott BL; Estey E Oncology (Williston Park); 2008 Nov; 22(12):1344-52. PubMed ID: 19086598 [TBL] [Abstract][Full Text] [Related]
10. Myelodysplastic syndromes (MDS). Klimek V Best Pract Res Clin Haematol; 2015 Mar; 28(1):1-2. PubMed ID: 25659724 [No Abstract] [Full Text] [Related]
11. The myelodysplastic syndromes: the era of understanding. Meers S Eur J Haematol; 2015 May; 94(5):379-90. PubMed ID: 25186093 [TBL] [Abstract][Full Text] [Related]
12. Optimal sequencing of treatments for patients with myelodysplastic syndromes. Itzykson R; Fenaux P Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268 [TBL] [Abstract][Full Text] [Related]
13. New agents in the treatment of MDS. List AF Clin Adv Hematol Oncol; 2005 Nov; 3(11):832-4. PubMed ID: 16491623 [No Abstract] [Full Text] [Related]
14. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Silverman LR; Mufti GJ Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236 [TBL] [Abstract][Full Text] [Related]
15. Evaluating new treatment options for MDS. Garcia-Manero G; Yang AS; Jagasia M Clin Adv Hematol Oncol; 2007 Nov; 5(11):1-9; quiz 10-2. PubMed ID: 18185491 [TBL] [Abstract][Full Text] [Related]
16. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Estey EH Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301 [TBL] [Abstract][Full Text] [Related]
17. How I treat patients with myelodysplastic syndromes. Stone RM Blood; 2009 Jun; 113(25):6296-303. PubMed ID: 19383969 [No Abstract] [Full Text] [Related]
18. Evolving treatment options of myelodysplastic syndromes. Verbeek W; Ganser A Ann Hematol; 2001 Sep; 80(9):499-509. PubMed ID: 11669297 [TBL] [Abstract][Full Text] [Related]
20. Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse? DeZern AE Hematology Am Soc Hematol Educ Program; 2015; 2015():308-16. PubMed ID: 26637738 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]